DOI: 10.12890/2022_003625

Premature Ventricular Contractions and Cardiomyopathy while on Ofatumumab for Treatment of Chronic Lymphocytic Leukaemia

Authors

  • Oladipo Odeyinka Rush University Medical Center, Chicago, IL, USA
  • Mitchell Collins Rush University Medical Center, Chicago, IL, USA
  • Michael Sunnaa Rush University Medical Center, Chicago, IL, USA
  • Parameswaran Venugopal Rush University Medical Center, Chicago, IL, USA
  • Tochukwu Okwuosa Rush University Medical Center, Chicago, IL, USA

odeyinkadipo@gmail.com

Keywords

Premature ventricular contraction, ofatumumab, chronic lymphocytic leukemia

Abstract

Ofatumumab is a monoclonal antibody used in the treatment of recurrent and progressive chronic lymphocytic leukaemia (CLL) and was recently approved for the treatment of multiple sclerosis.

We describe the case of a 68-year-old man who presented with complaints of irregular pulse readings while undergoing ofatumumab treatment for recurrent CLL. Electrocardiograms (ECGs) demonstrated premature ventricular contractions (PVCs) which eventually caused cardiomyopathy and failed to resolve despite ablative therapy. Ofatumumab-induced PVCs are confirmed in this case by the existence of documented PVCs on ECGs and the disappearance of these PVCs after the completion of ofatumumab treatment.

To the best of our knowledge, there have been no previously reported cases of PVCs associated with ofatumumab in the literature. 

View the entire article

Downloads

References

  1. Robak T, Warzocha K, Govind Babu K, Kulyaba Y, Kuliczkowski K, Abdulkadyrov K, et al. Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial. Leuk Lymphoma 2017 May 4;58(5):1084–1093. Available from: https://pubmed.ncbi.nlm.nih.gov/27731748/
  2. Buza V, Rajagopalan B, Curtis AB. Cancer treatment–induced arrhythmias. Circ Arrhythm Electrophysiol 2017 Aug 1;10(8):e005443. Available from: https://www.ahajournals.org/doi/abs/10.1161/CIRCEP.117.005443
  3. Jewell RC, Laubscher K, Lewis E, Fang L, Gafoor Z, Carey J, et al. Assessment of the effect of ofatumumab on cardiac repolarization. J Clin Pharmacol 2015;55(1):114–121. Available from: https://pubmed.ncbi.nlm.nih.gov/25103870/
  4. Takahashi J, Kawashima R, Abe Y, Fukuda H, Kubota K, Yamada K, et al. [Ventricular premature contraction observed after anti-cancer chemotherapy with ifosfamide.]Gan To Kagaku Ryoho 1994 Aug;21(10):1681–1684. Available from: https://pubmed.ncbi.nlm.nih.gov/7520222/
  5. Poterucha JT, Westberg M, Nerheim P, Lovell JP. Rituximab-induced polymorphic ventricular tachycardia. Tex Heart Inst J 2010;37(2):218. Available from: /pmc/articles/PMC2851419/
  6. Novartis. FDA approves Novartis Kesimpta® (ofatumumab), the first and only self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis. Available from: https://novartis.gcs-web.com/FDA-approves-Novartis-Kesimpta-ofatumumab-the-first-and-only-self-administered-targeted-B-cell-therapy-for-patients-with-relapsing-multiple-sclerosis (accessed 6 Sept 2022).

Published

2022-11-14

Issue

Vol. 9 No. 11 (2022)

How to Cite

1.
Odeyinka O, Collins M, Sunnaa M, Venugopal P, Okwuosa T. Premature Ventricular Contractions and Cardiomyopathy while on Ofatumumab for Treatment of Chronic Lymphocytic Leukaemia. EJCRIM [Internet]. 2022 Nov. 14 [cited 2026 Nov. 3];9(11). Available from: https://ejcrim.com/index.php/ejcrim/article/view/3625

Most read articles by the same author(s)